GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Hester Biosciences Ltd
Financial Results
RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 15 May 2026, 11:50 AM IST  ·  BSE ID: 02e0fd77-8efb-4275-b5ea-1ed17d51cb4f
View Original BSE Filing (PDF)
💡
In Simple Terms
Hester Biosciences reported full-year profits of INR 521.00 Million and proposed an INR 11 dividend per share.
🤖 AI Summary
  • Hester Biosciences FY26 standalone profit after tax stood at INR 521.00 Million.
  • Board recommended an INR 11 (110%) dividend per equity share for FY26, subject to shareholder approval.
  • Ms. Priya Gandhi's re-appointment as Executive Director for three years from October 28, 2026, was recommended.
  • Audited standalone revenue from operations for FY26 was INR 2,921.36 Million.
  • Total standalone comprehensive income for FY26 was INR 520.50 Million.
🔢 Key Numbers — exact figures from BSE filing, not rounded
FY26 Standalone Profit after exceptional item and tax
INR 521.00 Million
FY25 Standalone Profit after exceptional item and tax
INR 318.42 Million
FY26 Standalone Revenue from Operations
INR 2,921.36 Million
FY25 Standalone Revenue from Operations
INR 2,864.66 Million
Recommended Dividend per share for FY26
INR 11
FY26 Standalone Earnings Per Share (Basic & Diluted)
INR 61.24
FY25 Standalone Earnings Per Share (Basic & Diluted)
INR 37.43
Standalone Total Assets as at 31 March 2026
INR 5,573.46 Million
Standalone Total Equity as at 31 March 2026
INR 3,851.82 Million
🏢 How This Affects the Company
💰
Financial Impact
The approved full-year financial results reflect the company's performance, with a standalone profit after tax of INR 521.00 Million for FY26. The recommended dividend of INR 11 per share would result in a cash outflow upon approval and payment.
⚙️
Operational Impact
The re-appointment recommendation for Ms. Priya Gandhi as Executive Director maintains continuity in leadership and strategic direction for another three-year term, effective October 28, 2026.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must approve the recommended dividend and Ms. Priya Gandhi's re-appointment at the upcoming Annual General Meeting.
👤
Who Is Affected
All shareholders will be affected by the dividend approval, as it determines the distribution of INR 11 per equity share. Shareholders will vote on the proposed re-appointment of Ms. Priya Gandhi.
🔍
Management Signal
The dividend recommendation signals management's confidence in the company's financial performance and commitment to shareholder returns. The re-appointment indicates a preference for leadership continuity.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Annual General Meeting date — for shareholder approval of dividend and re-appointment.
Dividend record date — to confirm eligibility for the proposed dividend.
Dividend payment date — to track actual disbursement to shareholders.
LOW RISK The filing reports annual results and routine board decisions, without indicating new or elevated risks.
💡 Investor Takeaway
Hester Biosciences reported audited standalone profit after tax of INR 521.00 Million for FY26, an increase from INR 318.42 Million in FY25. The Board recommended an INR 11 per equity share dividend for FY26, pending shareholder approval. Ms. Priya Gandhi's re-appointment as Executive Director for three years was also proposed.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone profit after exceptional item and tax for FY26 increased to INR 521.00 Million compared to INR 318.42 Million in FY25.
  • Company proposed a dividend of INR 11 per equity share, equivalent to 110% of the face value of INR 10 each, for FY26.

⚠️ Concerns

  • Standalone current liabilities increased to INR 919.18 Million as of March 31, 2026, from INR 967.02 Million as of March 31, 2025.
  • Standalone total current assets for FY26 remained at INR 1,897.64 Million, showing a marginal increase from INR 1,852.35 Million in FY25.
📅 Company Track Record
Hester Biosciences reported standalone profit after tax of INR 521.00 Million for FY26, following INR 318.42 Million in FY25. An INR 11 dividend has been proposed for FY26. The previous filing on May 15, 2026, had also indicated FY26 standalone profit after tax at INR 521.00 Million and proposed an INR 11 dividend.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.